In a murine model of Ph+ ALL, imatinib treatment resulted in BCL6 upregulation and downregulation of p53, while genetic inactivation of BCL6 resulted in increased levels of p53 and failure to cause leukemia in mice. The gene discussed is BCL6; the disease is leukemia.